Last Updated: 06-07-2022 8:10
In order to come up with a suggested list of biomarkers, matrices and analytical methods for the 1st prioritisation round of substances, partners in task 9.1 in collaboration with the chemical group leaders (CGLs) made inventories of available analytical methods as well as suitable exposure biomarkers and matrices. Information in the inventories was further evaluated by partners in task 9.1 following guidelines that had been thoroughly discussed and agreed upon. The CGLs were consulted and gave their input on the final draft of the deliverable. The substances have been categorised according to the year one scoping documents. Category C substances for which information on analytical methods in human matrices are insufficient or lacking, have been left out. The inventories and evaluations are revised and updated both in the year 2018 and 2021. Further, the progress made with respect to analytical quality and harmonization/comparability of methods as a result of the QA/QC program in task 9.4 is also elaborated, to show the capabilities of European laboratories to perform human biomonitoring of the prioritized substances on the first list.